I wouldnt recommend semaglutide for AUD in isolation, but if a patient meets BMI or blood sugar criteria for use, and over-drinking is an issue, its a win-win medication, she said
These statements have not been evaluated by the Food & Drug Administration
Clinical trials have shown significant reductions in baseline body weight over extended treatment durations, particularly when dosing is escalated gradually under medical supervision
For organizations navigating the GLP-1 landscape specifically, Cypris enables continuous monitoring of poly-agonist patent filings, delivery technology innovations, and combination therapy claims across global jurisdictions
The company has reformulated the drug to improve tolerability, reflecting the industry's broader effort to develop more patient-friendly alternatives to injectable therapies